RedHill Biopharma (RDHL) Tops Q3 EPS Views; Announces RIZAPORT Marketing Approval in Germany
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
RedHill Biopharma Reports Results for the Third Quarter of 2015
November 9, 2015 7:00 AM ESTKey Highlights Include:
A strong cash position of approximately $64 million at the end of the third quarter of 2015 following the Company's July 2015 public offering in the U.S. with gross proceeds of $44.5 million Recent key milestones include the first European marketing approval of RIZAPORT announced today, positive top-line results from the Phase I study with YELIVA (ABC294640) in advanced solid tumors and the initiation of a Phase I/II study with YELIVA for diffuse large B-cell lymphoma RedHill continues to advance the... MoreRedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
November 9, 2015 6:00 AM ESTThe German Federal Institute for Drugs and Medical Devices (BfArM) has granted national marketing approval for RIZAPORT (RHB-103) for the treatment of acute migraines under the European Decentralized Procedure (DCP) RedHill and IntelGenx continue their close cooperation in order to obtain approvals in additional European countries and in the U.S., where a New Drug Application (NDA) was submitted and a Complete Response Letter was received RedHill and IntelGenx continue to advance their activities to secure commercialization partners in Europe, the U.S. and additional territories... More
